From Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs:

Karyopharm

Karyopharm—

Karyopharm Therapeutics is developing cancer drugs.

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Video
Fish & Richardson: Patent Law in Regards to AI and Machine Learning
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Xconomy on Demand

We offer a number of ways to subscribe for free!